Advertisement
Advertisement
CORT
Corcept Therapeutics Inc.
33.81
USDSponsored
+0.18
+0.52%
Mar 24, 15:59 UTC -4
Closed
After-Market
33.80
-0.01
-0.03%
CORT Earnings Reports
Positive Surprise Ratio
CORT beat 26 of 41 last estimates.
63%
Next Report
Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$196.36M
/-$0.01
Implied change from Q4 25 (Revenue/ EPS)
-2.85%
/-105.00%
Implied change from Q1 25 (Revenue/ EPS)
+24.90%
/-105.88%
Corcept Therapeutics Inc. earnings per share and revenue
On Feb 24, 2026, CORT reported earnings of 0.20 USD per share (EPS) for Q4 25, missing the estimate of 0.30 USD, resulting in a -34.64% surprise. Revenue reached 202.13 million, compared to an expected 260.03 million, with a -22.27% difference. The market reacted with a -0.71% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of -0.01 USD, with revenue projected to reach 196.36 million USD, implying an decrease of -105.00% EPS, and decrease of -2.85% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nektar Therapeutics
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$2.52
Actual
-$1.78
Surprise
+29.47%
Oruka Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.64
Actual
-$0.45
Surprise
+29.69%
Savara Inc.
Report Date
Mar 13, 2026 For Q4 25
Estimate
-$0.12
Actual
-$0.13
Surprise
-8.15%
Lyell Immunopharma, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$2.27
Actual
-$7.50
Surprise
-229.53%
Relmada Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.14
Actual
-$0.27
Surprise
-89.08%
Century Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.28
Actual
-$0.22
Surprise
+23.88%
Tonix Pharmaceuticals Holding Corp.
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$3.25
Actual
-$3.98
Surprise
-22.32%
Korro Bio, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$2.10
Actual
-$1.65
Surprise
+21.74%
Verrica Pharmaceuticals Inc. Common Stock
Report Date
Mar 11, 2026 For Q4 25
Estimate
-$0.81
Actual
-$0.46
Surprise
+43.22%
Champions Oncology, Inc.
Report Date
Mar 12, 2026 For Q3 26
Estimate
$0.09
Actual
-$0.02
Surprise
-121.79%
FAQ
What were Corcept Therapeutics Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Corcept Therapeutics Inc. reported EPS of $0.20, missing estimates by -34.64%, and revenue of $202.13M, -22.27% below expectations.
How did the market react to Corcept Therapeutics Inc.'s Q4 2025 earnings?
The stock price moved down -0.71%, changed from $36.48 before the earnings release to $36.22 the day after.
When is Corcept Therapeutics Inc. expected to report next?
The next earning report is scheduled for May 04, 2026.
What are the forecasts for Corcept Therapeutics Inc.'s next earnings report?
Based on 7
analysts, Corcept Therapeutics Inc. is expected to report EPS of -$0.01 and revenue of $196.36M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement